By Therapeutic Area

Rare Disease & Orphan (incl. Hemophilia) Market Analysis

Cross-industry research covering Rare Disease & Orphan (incl. Hemophilia) across 1 market reportspanning Pharmaceuticals & Diagnostics.

1 Reports
1 Industries

Reports Covering Rare Disease & Orphan (incl. Hemophilia)

Hematology Analyzers and Reagents Market to Reach USD 8.9 Billion by 2033 at 6.4% CAGR

Pharmaceuticals & Diagnostics·Market: USD 5.4 Billion (2025)·CAGR: 6.4%

Hemophilia A and B, sickle cell disease, and beta-thalassemia each require specialized coagulation and CBC monitoring. Pfizer's Phase 3 gene therapy program for hemophilia B (NCT03861273) could, at scale, reduce monitoring intensity for successfully transduced patients, a slow-burn volume headwind for this sub-segment.

8%

Market Share

6.2%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments